ArticleBlood advances2024

Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.

Birte Wistinghausen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.